Embark Technology Q2 EPS $(0.03) Beats $(0.09) Estimate

Embark Technology (NASDAQ:EMBK) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent.

Embark Technology (NASDAQ:EMBK) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent.

Total
0
Shares
Related Posts
Read More

Bristol Myers Squibb Provides Update On RELATIVITY-123 Trial Evaluating The Fixed-Dose Combination Of Nivolumab And Relatlimab In Patients With Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic

BMY